Top Page
Zoono Group Limited
(Sydney:ZNO)
Zoono Group Limited (ZNO) vs. iShares MSCI Australia ETF (EWA)
Zoono Group Limited Business Overview & Revenue Model
Zoono Group Limited Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.14M | 1.16M | 960.30K | 3.07M | 8.13M | 25.22M |
| Gross Profit | -289.16K | -281.53K | -4.36M | -625.33K | 2.10M | 11.88M |
| EBITDA | -3.23M | -3.26M | -7.89M | -181.62K | -5.11M | 5.89M |
| Net Income | -3.61M | -3.64M | -8.30M | -321.97K | -10.28M | 4.40M |
Balance Sheet | ||||||
| Total Assets | 5.87M | 5.87M | 9.01M | 13.40M | 17.68M | 29.46M |
| Cash, Cash Equivalents and Short-Term Investments | 47.30K | 47.30K | 1.79M | 759.99K | 3.30M | 4.55M |
| Total Debt | 544.56K | 544.56K | 726.63K | 868.99K | 1.00M | 1.93M |
| Total Liabilities | 2.89M | 2.89M | 2.76M | 3.24M | 8.41M | 9.88M |
| Stockholders Equity | 2.97M | 2.97M | 6.24M | 10.16M | 10.00M | 19.68M |
Cash Flow | ||||||
| Free Cash Flow | -1.55M | -1.58M | -2.89M | -3.55M | -996.61K | 834.07K |
| Operating Cash Flow | -1.55M | -1.58M | -2.89M | -3.55M | -974.11K | 1.38M |
| Investing Cash Flow | 0.00 | 0.00 | -58.73K | -53.49K | -107.62K | -1.26M |
| Financing Cash Flow | -190.66K | -190.15K | 3.99M | 873.62K | -54.99K | ― |
Zoono Group Limited Technical Analysis
Zoono Group Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
46 Neutral | AU$30.47M | -7.43 | -77.92% | ― | 17.41% | 67.94% | |
45 Neutral | AU$15.00M | ― | ― | ― | 12.92% | 34.21% | |
43 Neutral | AU$7.33M | -0.67 | ― | ― | -21.84% | 79.99% | |
37 Underperform | AU$15.29M | ― | -555.97% | ― | 88.48% | 51.61% |
Zoono Group Limited Corporate Events
Zoono Group Limited has responded to an ASX price query by outlining how it monitors and discloses its dealings under its exclusive agency agreement with OSY Group, stressing that it remains fully compliant with continuous disclosure obligations and maintains detailed visibility over trials, negotiations and customer orders. While the company has begun to receive small, non-material orders under the OSY agreement in FY26 and has secured exclusive packaging contracts in the UK, South Africa and Australia, it confirmed that no OSY-related revenue was recorded in FY25 and that minimum sales benchmarks in key regions have not yet been met due to slower-than-expected adoption by major UK supermarket chains, rather than any failure of the technology or the partners; nonetheless, Zoono is continuing the OSY arrangement, expects orders to build over FY26 toward agreed targets, and has reaffirmed that it will update the market if material orders are received.
Zoono Group Limited held its Annual General Meeting, emphasizing its commitment to improving health and well-being through innovative germ protection solutions. The company’s focus on scientifically validated, long-lasting antimicrobial products positions it strongly in the global market, with implications for enhanced stakeholder confidence and potential growth in the biotech industry.
Zoono Group Limited has requested a trading halt on its securities pending a response to a Price Query from the ASX. The halt will remain in effect until either the start of trading on November 14, 2025, or the release of the company’s response. This move indicates a significant development that could impact the company’s stock and stakeholders, highlighting the importance of the forthcoming announcement.
Zoono Group Limited has signed an exclusive five-year contract with Mpact Operations in South Africa and Namibia, alongside its partner OSY Group Limited. This agreement focuses on using Zoono’s antimicrobial products in corrugated board-based packaging for grapes, stone fruit, and berries, aiming to extend shelf-life and reduce food waste. This partnership marks a strategic expansion into new markets, building on previous successes in the UK and EU, and highlights the growing commercial adoption of Zoono’s technology. The collaboration is expected to deliver significant benefits across the food supply chain, including financial savings and enhanced product freshness for supermarkets.
Zoono Group Limited has announced the cessation of 1,900,000 securities due to the expiry of options that were not exercised or converted by November 1, 2025. This cessation of securities may impact the company’s capital structure, but it is a routine financial adjustment that does not directly affect its operational activities or market position.
Zoono Group Limited has made significant progress in its fresh food shelf-life extension technology, conducting successful trials across the UK, Europe, Asia, Africa, and Australia. The company anticipates the first material sales revenues from these products in the current quarter, signaling potential long-term revenue streams. Additionally, Zoono is advancing in Asian markets with new orders from Japan and India, and expects improved sales revenues in the first half of FY26, supported by recent funding and lower operating costs.
Zoono Group Limited announced the cessation of 3,500,000 securities, specifically options that expired on June 30, 2025, without being exercised or converted. This development may impact the company’s capital structure and could influence investor perceptions regarding the company’s financial strategies and market positioning.
Zoono Group Limited has announced its 2025 Annual General Meeting (AGM) scheduled for November 20, 2025, in Sydney. The AGM will address the company’s annual financial report and a non-binding advisory resolution on the remuneration report. This meeting is significant for shareholders as it provides insights into the company’s financial health and governance practices, potentially impacting stakeholder confidence and future strategic decisions.
Zoono Group Limited has addressed a price query from the ASX regarding the recent increase in the price and trading volume of its securities. The company stated that it is not aware of any undisclosed information that could explain the trading activity. Zoono continues to work on its shelf-life extension project with OSY Group Ltd and other partners across multiple continents, with ongoing trials showing positive results. The company anticipates signing several significant supply agreements in the coming year, which could impact its market positioning and stakeholder interests.